Altimmune (ALT) Interest Coverage Ratio Growth (3y) (2013 - 2026)
Powered by 
Analysis
Altimmune (ALT) Interest Coverage Ratio Growth (3y) (2013 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 29.79% |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn | -44.22% |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - | - |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn | 33.30% |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | -35.50% |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn | 81.16% |
| 10 | Altimmune | 626.82 Mn | 626.82 Mn | - | 86.15% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 86.15% |
| Mar 31, 2026 | 87.22% |
| Dec 31, 2025 | -31.26% |
| Sep 30, 2025 | 52.24% |
| Jun 30, 2025 | 34.84% |
| Mar 31, 2025 | -310.88% |
| Dec 31, 2024 | -304.69% |
| Sep 30, 2024 | -60.08% |
| Jun 30, 2024 | -187.10% |
| Mar 31, 2024 | -178.65% |
| Dec 31, 2023 | -45.09% |
| Sep 30, 2023 | 54.13% |
| Jun 30, 2023 | -17.38% |
| Mar 31, 2023 | -41.06% |
| Sep 30, 2022 | 70.40% |
| Jun 30, 2022 | 59.57% |
| Mar 31, 2022 | 53.59% |
| Dec 31, 2021 | 56.07% |
| Sep 30, 2021 | -245.92% |
| Jun 30, 2021 | 26.36% |